Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58

被引：0
|
作者：
Zelniker, Thomas A.
Morrow, David A.
Mosenzon, Ofri
Goodrich, Erica
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P.
Gause-Nilsson, Ingrid A.
Langkilde, Anna Maria
Raz, Itamar
Sabatine, Marc S.
Wiviott, Stephen D.
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A15670
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
    Patel, Siddharth M.
    Morrow, David A.
    Bellavia, Andrea
    Berg, David D.
    Bhatt, Deepak L.
    Jarolim, Petr
    Leiter, Lawrence A.
    McGuire, Darren K.
    Raz, Itamar
    Steg, P. Gabriel
    Wilding, John P. H.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    Braunwald, Eugene
    Scirica, Benjamin M.
    Bohula, Erin A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 260 - 269
  • [22] Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
    Pollack, Rena
    Raz, Itamar
    Wiviott, Stephen D.
    Goodrich, Erica L.
    Murphy, Sabina A.
    Yanuv, Ilan
    Rozenberg, Aliza
    Mosenzon, Ofri
    Langkilde, Anna Maria
    Gause-Nilsson, Ingrid A. M.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Sabatine, Marc S.
    Cahn, Avivit
    DIABETES CARE, 2023, 46 (01) : 156 - 164
  • [23] Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
    Bonaca, Marc P.
    Wiviott, Stephen D.
    Zelniker, Thomas A.
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Goodrich, Erica L.
    De Mendonca Furtado, Remo Holanda
    Wilding, John P. H.
    Cahn, Avivit
    Gause-Nilsson, Ingrid A. M.
    Johanson, Per
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    CIRCULATION, 2020, 142 (08) : 734 - 747
  • [24] Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
    Zelniker, T. A.
    Raz, I.
    Mosenzon, O.
    Dwyer, J. P.
    Heerspink, H. J. L.
    Cahn, A.
    Im, K.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Gause-Nilsson, I. A. M.
    Langkilde, A. M.
    Sabatine, M. S.
    Wiviott, S. D.
    EUROPEAN HEART JOURNAL, 2019, 40 : 54 - 54
  • [25] Assessing the Performance of the UKPDS 82 Risk Equations to Predict Cardiovascular Events in the DECLARE-TIMI 58 Trial Population
    Mcewan, Philip
    Foos, Volker, Sr.
    Bennett, Hayley
    Kartman, Bernt
    Edmonds, Christopher
    Gause-Nilsson, Ingrid Anna
    DIABETES, 2019, 68
  • [26] Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
    Cahn, Avivit
    Raz, Itamar
    Leiter, Lawrence A.
    Mosenzon, Ofri
    Murphy, Sabina A.
    Goodrich, Erica L.
    Yanuv, Ilan
    Rozenberg, Aliza
    Bhatt, Deepak L.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES CARE, 2021, 44 (05) : 1159 - 1167
  • [27] Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
    Zelniker, T.
    Raz, I.
    Mosenzon, O.
    Dwyer, J.
    Heerspink, H.
    Cahn, A.
    Im, K.
    Deepak, B.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Gause-Nilsson, I.
    Langkilde, A. M.
    Sabatine, M.
    Wiviott, S.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S175 - S175
  • [28] Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
    Oyama, Kazuma
    Wiviott, Stephen D.
    Raz, Itamar
    Cahn, Avivit
    Goodrich, Erica
    Bhatt, Deepak L.
    Leiter, Lawrence
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Bohula, Erin A.
    CIRCULATION, 2020, 142
  • [29] Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
    Kolkailah, Ahmed A.
    Wiviott, Stephen D.
    Raz, Itamar
    Murphy, Sabina A.
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid
    Sabatine, Marc S.
    McGuire, Darren K.
    DIABETES CARE, 2022, 45 (02) : E27 - E29
  • [30] Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
    Furtado, Remo H. M.
    Raz, Itamar
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Aylward, Philip
    Dalby, Anthony J.
    Dellborg, Mikael
    Dimulescu, Doina
    Nicolau, Jose C.
    Oude Ophuis, Anthonius J. M.
    Cahn, Avivit
    Mosenzon, Ofri
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2022, 145 (21) : 1581 - 1591
12345